Safety and Outcomes analysis: transcatheter implantation of autologous angiogenic cell precursors for the treatment of cardiomyopathy
Stem cell transplantation is an emerging therapy for severe cardiomyopathy, proffering stem cell recruitment, anti-apoptosis, and proangiogenic capabilities.
Jane R. Schubart, Amirhossein Zare, Roberto M. Fernandez-de-Castro, Hector Rosario Figueroa, Ina Sarel, Kelly Tuchman, Kaitlyn Esposito, Fraser C. Henderson & Ernst von Schwarz
Cytotherapy 2013
Peripheral blood-derived autologous stem cell therapy for the treatment of patients with late-stage peripheral artery disease-results of the short- and long-term follow-up
G.V. Szabó, Z. Kövesd, J. Cserepes, J. DaróczyM. Belkin M, and G. Acsády
BioProcessing Journal 2007
Challenges in the Development of Autologous Cell Therapy Products
Y. Porat, D. Belkin, A. Belleli, J. Elkayam, D. Shimoni, S. Porozov, I. Sarel, I. Ash, and V. Fulga
Hemostemix ACP-01 Publication
Autologous Stem Cell Treatment For CLI Patients With No Revascularization Options
(An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup)
Jonathan Misskey MD MHPE FRCSC, Lynn Cunada, RN, Kyle Makofka, Alan Jacobs MSEE MD PhD,
Thomas Lindsay MDCM, MSc, FRCSC, York N. Hsiang, MB ChB, MHSc., FRCSCS
Asian Annals
Intramyocardial Angiogenic Cell Precursor Injection for Cardiomyopathy
Kitipan V Arom, Permyos Ruengsakulrach and Vibul Jotisakulratana
Asian Cardiovasc Thorac Ann 2008;16:143-148
BJH research paper
Isolation of an adult blood-derived progenitor cell population
capable of differentiation into angiogenic, myocardial and
neural lineages
Panama College of Cell Science
Transcoronary Injection of Angiogenic Cells Precursors an Autologous Stem Cell in Ischemic Cardiomyopathy: A Clinical study of 106 cases in Thailand
Angiogenic Precursor Cell Treatment of Critical Limb Ischemia Decreases Ulcer Size, Amputation and Death Rate: Re-Examination of phase II ACP NO-CLI Trial Data
Critical limb ischemia has a prevalence in the US of 1.33%, with mortality 15-20%
and major amputation 10-40% per year. Stem cell treatment has emerged as a treatment option for
the 45% of patients for whom revascularization procedures are not possible.
Objective: This study re-examines the data of the Phase II clinical treatment of no opti
